Please assess the completion status of the following clinical trial:

Trial Title: A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Concomitant Administration of Sitagliptin and Metformin as Individual Tablets (0431A-048)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Female subjects of reproductive potential test negative for pregnancy and agree to use appropriate contraception~* Subject is in good health and is a non-smoker~* Subject is willing to avoid strenuous physical activity during the study~* Subject agrees to refrain from eating grapefruit or grapefruit products during the study~Exclusion Criteria:~* Subject has a history of neoplastic disease (cancer), stroke, chronic seizures, or major neurological disorder. Subject has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases~* Subject consumes excessive amounts of alcohol or caffeinated beverages~* Subject has donated blood, had surgery or participated in another clinical study within the past 4 weeks~* Subject has a history of significant multiple and/or severe allergies to prescription or non-prescription drugs or food~* Subject has a history of hypersensitivity to metformin, sitagliptin, or sitagliptin/Metformin~* Subject is a regular user or past abuser of any illicit drugs~* Subject is unable to refrain from or anticipates the use of any medication, including prescription and non-prescription drugs or herbal remedies during the study.~* Subject is a nursing mother

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Treatment A (Type: ACTIVE_COMPARATOR): Individual Tablets of 50 mg sitagliptin and 500 mg metformin
- Treatment B (Type: EXPERIMENTAL): Sitagliptin/metformin 50 mg/500 mg tablet
- Treatment C (Type: ACTIVE_COMPARATOR): Individual Tablets of 50 mg sitagliptin and 1000 mg metformin
- Treatment D (Type: EXPERIMENTAL): sitagliptin/metformin 50 mg/1000 mg tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).